Myriad Genetics Inc (MYGN) 30.95 $MYGN
Crescendo Bioscience Announces that New Data on Vectra(R) DA Will Be Presented at the European League Against Rheumatism 17th Annual Congress
GlobeNewswire - Fri Jun 10, 6:05AM CDT
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra DA test to predict treatment response in patients with rheumatoid arthritis (RA) are being presented at European League Against Rheumatism (EULAR) meeting being held June 8-11, 2016, in London. Vectra DA test is the first and only multi-biomarker blood test validated to measure disease activity in patients with RA and has been evaluated in multiple studies, resulting in 23 scientific peer-reviewed publications.
MYGN: 30.95 (-3.07)
Myriad Board Approves $200 Million Increase in Share Repurchase Program
GlobeNewswire - Tue Jun 07, 6:05AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its board of directors has approved an additional $200 million authorization for its share repurchase program. As of the end of the third quarter of fiscal year 2016, the Company had repurchased greater than $1.1 billion of stock since the inception of the program in 2010 at an average share price of $26.16.
MYGN: 30.95 (-3.07)
Myriad Genetics to Present at the 2016 Goldman Sachs Healthcare Conference
GlobeNewswire - Mon Jun 06, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Healthcare Conference at 10:00 a.m. Pacific on June 8, 2016, at the Terranea Resort in Rancho Palos Verdes, California.
MYGN: 30.95 (-3.07)
Myriad myRisk(R) Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk in Nearly 100,000 Patients
GlobeNewswire - Mon Jun 06, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that two analyses demonstrating the utility of the Myriad myRisk Hereditary Cancer test will be featured in oral presentations at the 2016 American Society of Clinical Oncology annual meeting. These presentations demonstrate the importance of using a 25-gene panel to evaluate risk for hereditary breast and ovarian cancers.
MYGN: 30.95 (-3.07)
Myriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting
GlobeNewswire - Sun Jun 05, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies with the Myriad myRisk Hereditary Cancer test will be featured in podium presentations at the 2016 American Society of Clinical Oncology annual meeting. These presentations demonstrate the expanding benefits of gene panel testing and underscore the need for gene panel testing to become the standard-of-care for hereditary cancer risk evaluation.
MYGN: 30.95 (-3.07)
Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), MYGN: 30.95 (-3.07), BAX: 44.49 (-0.26)
After Yesterday's Rally of 1.25% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:53PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $34.27 to a high of $34.78. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $34.49 on volume of 779,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYGN: 30.95 (-3.07)
Myriad Acquires Sividon Diagnostics
Globe Newswire - Tue May 31, 3:05PM CDT
Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict(R)
MYGN: 30.95 (-3.07)
Watch for Myriad Genetics to Potentially Rebound After Falling 2.83% Yesterday
Comtex SmarTrend(R) - Thu May 26, 3:24PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.92 to a high of $35.13. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $34.01 on volume of 363,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 30.95 (-3.07)
After Yesterday's Decline of 2.83%, Myriad Genetics Offers Investors Better Value
Comtex SmarTrend(R) - Thu May 26, 3:22PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.92 to a high of $35.13. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $34.01 on volume of 363,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 30.95 (-3.07)
Myriad Genetics' Statement on HIPAA Complaint from Four Patients
GlobeNewswire - Thu May 19, 3:56PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a complaint was filed against the Company with the Department of Health and Human Services on behalf of four individuals seeking their genetic testing results. The Company believes it has complied with these requests and provided these four patients with their designated record set and all requested personal health information. Therefore, we believe the complaint lacks merit and should not be accepted.
MYGN: 30.95 (-3.07)
Myriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information
GlobeNewswire - Wed May 18, 4:56PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced plans to launch a new web portal on ms360.myriad.com that will allow patients to access their personal test results as well as other high-quality tools and ideas to help them make healthcare decisions.
MYGN: 30.95 (-3.07)
Myriad to Present New Research at the 2016 ASCO Annual Meeting
GlobeNewswire - Wed May 18, 4:05PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) today announced it will present data from nine clinical studies with three different products at the 2016 American Society of Clinical Oncology annual meeting to be held June 3-7, 2016 in Chicago, Ill. Key podium presentations will highlight the safety and validity of the Myriad myRisk Hereditary Cancer multigene panel test in assessing hereditary cancer risk. Abstracts of the Company's presentations are available at: abstracts.asco.org.
MYGN: 30.95 (-3.07)
Myriad Genetics Brings myVectra Web Portal for RA Patients
Zacks Equity Research - Zacks Investment Research - Tue May 17, 7:04AM CDT
Myriad's (MYGN) myVectra portal will offer easy access for its users to their Vectra DA test score, which in turn would keep the concerned RA patients better informed about the current status of their disease.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), MYGN: 30.95 (-3.07), BAX: 44.49 (-0.26)
Myriad Genetics: Test Revenues Strong, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:06AM CDT
Myriad (MYGN) ended the third quarter of fiscal 2016 on a promising note, beating the Zacks Consensus Estimate on both top and bottom-line fronts
BSX: 23.02 (-0.30), MYGN: 30.95 (-3.07), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06)
Crescendo Bioscience Launches Web Portal for Patients with Rheumatoid Arthritis
GlobeNewswire - Wed May 11, 6:05AM CDT
myVectra Enables Secure Access to Vectra DA Test Results
MYGN: 30.95 (-3.07)
Myriad to Present Three New Studies at the AUA Annual Meeting
GlobeNewswire - Fri May 06, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies will be featured at the American Urological Association annual meeting, which will take place May 6-10 in San Diego, Calif. Poster discussions include new data for the Prolaris test in patients with low-risk prostate cancer, as well as investigational molecular diagnostic tests for renal and bladder cancer.
MYGN: 30.95 (-3.07)
Myriad Genetics (MYGN) Tops Q3 Earnings, Narrows Outlook
Zacks Equity Research - Zacks Investment Research - Wed May 04, 8:08AM CDT
Myriad???s (MYGN) third quarter of fiscal 2016 has been quite satisfactory with both its top and bottom line comfortably beating the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), MYGN: 30.95 (-3.07), BAX: 44.49 (-0.26)
Crescendo Bioscience Announces that New Data on Vectra(R) DA Will Be Presented at the European League Against Rheumatism 17th Annual Congress
GlobeNewswire - Fri Jun 10, 6:05AM CDT
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra DA test to predict treatment response in patients with rheumatoid arthritis (RA) are being presented at European League Against Rheumatism (EULAR) meeting being held June 8-11, 2016, in London. Vectra DA test is the first and only multi-biomarker blood test validated to measure disease activity in patients with RA and has been evaluated in multiple studies, resulting in 23 scientific peer-reviewed publications.
MYGN: 30.95 (-3.07)
Myriad Board Approves $200 Million Increase in Share Repurchase Program
GlobeNewswire - Tue Jun 07, 6:05AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its board of directors has approved an additional $200 million authorization for its share repurchase program. As of the end of the third quarter of fiscal year 2016, the Company had repurchased greater than $1.1 billion of stock since the inception of the program in 2010 at an average share price of $26.16.
MYGN: 30.95 (-3.07)
Myriad Genetics to Present at the 2016 Goldman Sachs Healthcare Conference
GlobeNewswire - Mon Jun 06, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Healthcare Conference at 10:00 a.m. Pacific on June 8, 2016, at the Terranea Resort in Rancho Palos Verdes, California.
MYGN: 30.95 (-3.07)
Myriad myRisk(R) Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk in Nearly 100,000 Patients
GlobeNewswire - Mon Jun 06, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that two analyses demonstrating the utility of the Myriad myRisk Hereditary Cancer test will be featured in oral presentations at the 2016 American Society of Clinical Oncology annual meeting. These presentations demonstrate the importance of using a 25-gene panel to evaluate risk for hereditary breast and ovarian cancers.
MYGN: 30.95 (-3.07)
Myriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting
GlobeNewswire - Sun Jun 05, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies with the Myriad myRisk Hereditary Cancer test will be featured in podium presentations at the 2016 American Society of Clinical Oncology annual meeting. These presentations demonstrate the expanding benefits of gene panel testing and underscore the need for gene panel testing to become the standard-of-care for hereditary cancer risk evaluation.
MYGN: 30.95 (-3.07)
Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), MYGN: 30.95 (-3.07), BAX: 44.49 (-0.26)
After Yesterday's Rally of 1.25% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:53PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $34.27 to a high of $34.78. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $34.49 on volume of 779,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYGN: 30.95 (-3.07)
Myriad Acquires Sividon Diagnostics
Globe Newswire - Tue May 31, 3:05PM CDT
Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict(R)
MYGN: 30.95 (-3.07)
Watch for Myriad Genetics to Potentially Rebound After Falling 2.83% Yesterday
Comtex SmarTrend(R) - Thu May 26, 3:24PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.92 to a high of $35.13. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $34.01 on volume of 363,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 30.95 (-3.07)
After Yesterday's Decline of 2.83%, Myriad Genetics Offers Investors Better Value
Comtex SmarTrend(R) - Thu May 26, 3:22PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.92 to a high of $35.13. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $34.01 on volume of 363,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 30.95 (-3.07)
Myriad Genetics' Statement on HIPAA Complaint from Four Patients
GlobeNewswire - Thu May 19, 3:56PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a complaint was filed against the Company with the Department of Health and Human Services on behalf of four individuals seeking their genetic testing results. The Company believes it has complied with these requests and provided these four patients with their designated record set and all requested personal health information. Therefore, we believe the complaint lacks merit and should not be accepted.
MYGN: 30.95 (-3.07)
Myriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information
GlobeNewswire - Wed May 18, 4:56PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced plans to launch a new web portal on ms360.myriad.com that will allow patients to access their personal test results as well as other high-quality tools and ideas to help them make healthcare decisions.
MYGN: 30.95 (-3.07)
Myriad to Present New Research at the 2016 ASCO Annual Meeting
GlobeNewswire - Wed May 18, 4:05PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) today announced it will present data from nine clinical studies with three different products at the 2016 American Society of Clinical Oncology annual meeting to be held June 3-7, 2016 in Chicago, Ill. Key podium presentations will highlight the safety and validity of the Myriad myRisk Hereditary Cancer multigene panel test in assessing hereditary cancer risk. Abstracts of the Company's presentations are available at: abstracts.asco.org.
MYGN: 30.95 (-3.07)
Myriad Genetics Brings myVectra Web Portal for RA Patients
Zacks Equity Research - Zacks Investment Research - Tue May 17, 7:04AM CDT
Myriad's (MYGN) myVectra portal will offer easy access for its users to their Vectra DA test score, which in turn would keep the concerned RA patients better informed about the current status of their disease.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), MYGN: 30.95 (-3.07), BAX: 44.49 (-0.26)
Myriad Genetics: Test Revenues Strong, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:06AM CDT
Myriad (MYGN) ended the third quarter of fiscal 2016 on a promising note, beating the Zacks Consensus Estimate on both top and bottom-line fronts
BSX: 23.02 (-0.30), MYGN: 30.95 (-3.07), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06)
Crescendo Bioscience Launches Web Portal for Patients with Rheumatoid Arthritis
GlobeNewswire - Wed May 11, 6:05AM CDT
myVectra Enables Secure Access to Vectra DA Test Results
MYGN: 30.95 (-3.07)
Myriad to Present Three New Studies at the AUA Annual Meeting
GlobeNewswire - Fri May 06, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies will be featured at the American Urological Association annual meeting, which will take place May 6-10 in San Diego, Calif. Poster discussions include new data for the Prolaris test in patients with low-risk prostate cancer, as well as investigational molecular diagnostic tests for renal and bladder cancer.
MYGN: 30.95 (-3.07)
Myriad Genetics (MYGN) Tops Q3 Earnings, Narrows Outlook
Zacks Equity Research - Zacks Investment Research - Wed May 04, 8:08AM CDT
Myriad???s (MYGN) third quarter of fiscal 2016 has been quite satisfactory with both its top and bottom line comfortably beating the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), MYGN: 30.95 (-3.07), BAX: 44.49 (-0.26)
